Vol 45, No 2 (2014)
Prace poglądowe / Reviews
Published online: 2014-04-01
Leukaemic stem cells
DOI: 10.1016/j.achaem.2014.04.002
Acta Haematol Pol 2014;45(2):161-165.
Abstract
Acute myeloid leukaemia (AML) is a neoplasm originating in early haematopoietic progenitor cells. Each AML clone contains a subpopulation of leukaemic stem cells (LSCs). LSCs have the capacity to repopulate AML in NOD/SCID mice and regrow leukaemia in patients after remission period. LSCs are characterized by CD34+CD38-Lin-CD33+/-CD123+ immunophenotype. The currently available data show that LSCs play a pivotal role in drug resistance. Many studies and clinical trials are being conducted to eradicate LSCs using different forms of target therapy.
Keywords: Acute myeloid leukaemiaLeukaemic stem cellsTherapeutic targets